All Filters
Therapeutic Area
Therapeutic Area
Format
What are you looking for?
All Filters
Therapeutic Area
Therapeutic Area
Format
top

Prescribing information

This link will take you to the electronic medicines compendium (emc) website, which is a non-Novartis website.

Hero Banner. KISQALI® (ribociclib) logo.
Hero Banner. KISQALI® (ribociclib) logo.

Five-year outcomes from the NATALEE trial and HCP reactions to the data

Indications:1

 

  • KISQALI® (ribociclib) in combination with an aromatase inhibitor (AI), is indicated for the adjuvant treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer (eBC) at high risk of recurrence (see section 5.1 of the SmPC for eligibility criteria)

  • In pre/perimenopausal women, or in men, the AI should be combined with a luteinising hormone-releasing hormone (LHRH) agonist

KISQALI is not recommended to be used in combination with tamoxifen.

For information on the safety profile of KISQALI in eBC, click here.

Please refer to the Summary of Product Characteristics (SmPC) for the full safety profile and guidance regarding managing adverse events (AEs).

  • NATALEE 5-year results
  • HCP opinions

    Click the play button below to watch the video from Dr John Crown

    Join Dr John Crown as he discusses the 5-year data from NATALEE in patients with HR+/HER2– eBC.

    Kisqali John Crown 5 year data video VIDEO

    Click the play button below to watch HCPs react to the 5-year data

    See your peers’ initial opinions on the 5-year data from the NATALEE trial, presented at ESMO Congress 2025.

    Kisqali Vox Pops 5 year data video VIDEO

AI, aromatase inhibitor; eBC, early breast cancer; ESMO, European Society for Medical Oncology; HCP, healthcare professional; HER2–, human epidermal growth factor receptor 2-negative; HR+, hormone receptor-positive; LHRH, luteinising hormone-releasing hormone; SmPC, summary of product characteristics.

Reference

  1. KISQALI® (ribociclib) Summary of Product Characteristics.

UK | November 2025 | FA-11543305

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.